Drugs / VINS Polyvalent Antivenom
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01284855 | Apr 2011 → Oct 2012 | snakebite envenomation | CTU | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VINS Polyvalent Antivenom | “A Randomized, Double-blind, Clinical Trial of Two Dose Regimens of VINS Polyvalent Antivenom (ATC J06AA03) for the Treatment of Snake Bites With Neurotoxic Envenoming in Nepal” NCT01284855 ↗ |
| Known as | Anti Snake Venom Serum (ASVS) | “It is a randomized, double-blind, clinical trial comparing high and low initial doses of snake polyvalent antivenom also known as Anti Snake Venom Serum (ASVS).” NCT01284855 ↗ |
| Modality | Protein / enzyme biologic | “It is a randomized, double-blind, clinical trial comparing high and low initial doses of snake polyvalent antivenom also known as Anti Snake Venom Serum (ASVS).” NCT01284855 ↗ |
| Route | Intravenous | “given by intravenous (IV) push” PMID 31205473 ↗ May 2019 |